SynthesisBiomolecules & biomedicine2025
Association between prediabetes and thyroid cancer risk: A meta-analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prediabetes, characterized by intermediate hyperglycemia, is increasingly prevalent worldwide. While diabetes has been associated with a heightened risk of various cancers, the relationship between prediabetes and thyroid cancer remains ambiguous. This meta-analysis sought to assess whether prediabetes correlates with an elevated incidence of thyroid cancer. A systematic literature search was conducted across PubMed, Embase, Web of Science, Wanfang, and CNKI to identify longitudinal studies that compared the incidence of thyroid cancer in individuals with prediabetes to those with normoglycemia. Risk ratios (RRs) with 95% confidence intervals (CIs) were aggregated using a random-effects model. Subgroup and sensitivity analyses were performed to identify potential effect modifiers. Six prospective cohort studies, encompassing 5,743,849 participants, were included in the analysis. Overall, prediabetes was not significantly correlated with thyroid cancer incidence (RR = 1.04; 95% CI: 0.98-1.11; p = 0.23; I² = 53%). Subgroup analyses revealed no significant variations based on age, sex, region, follow-up duration, or definition of prediabetes. Notably, a significant association was identified in studies utilizing cancer registries or validated clinical diagnoses (RR = 1.29; 95% CI: 1.04-1.60), in contrast to studies relying solely on ICD-10 codes (RR = 1.01; 95% CI: 0.98-1.05; p for subgroup difference = 0.03). In conclusion, prediabetes was not linked to a significantly increased risk of thyroid cancer overall. However, a potential association was noted in studies employing clinically validated cancer diagnoses. These findings, derived from observational cohorts, should be interpreted cautiously, and further prospective research is necessary to elucidate any causal relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.